Cart
sales@molnova.com
Nemolizumab
CAS No. 1476039-58-3
Nemolizumab( —— )
Catalog No. M36686 CAS No. 1476039-58-3
Nemolizumab (CIM331) is a humanized monoclonal antibody targeting the human interleukin-31 receptor A, inhibiting IL-31 binding and subsequent signal transduction. It is useful for studying atopic dermatitis with pruritus.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 271 | Get Quote |
|
| 5MG | 417 | Get Quote |
|
| 10MG | 616 | Get Quote |
|
| 25MG | 908 | Get Quote |
|
| 50MG | 1279 | Get Quote |
|
| 100MG | 1683 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNemolizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionNemolizumab (CIM331) is a humanized monoclonal antibody targeting the human interleukin-31 receptor A, inhibiting IL-31 binding and subsequent signal transduction. It is useful for studying atopic dermatitis with pruritus.
-
DescriptionNemolizumab (CIM331) is a humanized antihuman interleukin-31 receptor A monoclonal antibody that inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorInterleukin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1476039-58-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Nakahara T, et, al. Nemolizumab and Atopic Dermatitis: the Interaction Between Interleukin-31 and Interleukin-31 Receptor as a Potential Therapeutic Target for Pruritus in Patients With Atopic Dermatitis. 2018;5:405–14.
molnova catalog
related products
-
Ramucirumab
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors,is also a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors.
-
SSAA09E3
SSAA09E3 is a novel inhibitor of SARS-CoV replication, acting by preventing fusion of the viral membrane with the host cellular membrane.
-
Pyrazinamine
Pyrazinamine is a synthetic intermediate that can be used in a variety of scientific research applications, including as a synthetic reagent and as a biochemical and physiological reagent.
